Analysts think RGNX stock price could increase by 405%
Mar 13, 2025, 11:25 AM
-11.84%
What does RGNX do
REGENXBIO, a clinical-stage biotechnology company based in Rockville, Maryland, specializes in gene therapy using its NAV Technology Platform for retinal, neuromuscular, and neurodegenerative diseases. Its key therapies include ABBV-RGX-314, RGX-202, and RGX-121.
14 analysts think RGNX stock price will increase by 404.65%. The current median analyst target is $33.66 compared to a current stock price of $6.67. The lowest analysts target is $14.14 and the highest analyst target is $54.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
